Isbn: 9780306457432 - integration of pharmaceutical discovery and development: case histories: 11 (7 risultati)

Perfeziona la tua ricerca

  • Libri (7)

  • Nuovo (7)

a

Fascia di prezzo personalizzata (EUR)

a

    • Lingua: Inglese

      Editore: Springer, 1998

      0306457431 / 9780306457432

      • Rilegato

      Da: Ria Christie Collections, Uxbridge, Regno UnitoRia Christie Collections

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 227,16

      EUR 13,17 spedizione 
      Spedito da Regno Unito a U.S.A.

      Quantità: Più di 20 disponibili

      Condizione: New. In.

    • Condizione: Nuovo

      EUR 307,80

      EUR 17,50 spedizione 
      Spedito da Regno Unito a U.S.A.

      Quantità: 2 disponibili

      Hardcover. Condizione: Brand New. 607 pages. 9.50x6.25x1.50 inches. In Stock.

    • Lingua: Inglese

      Editore: Springer US, 1998

      0306457431 / 9780306457432

      • Rilegato
      • Print on Demand

      Da: moluna, Greven, Germaniamoluna

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 180,07

      EUR 48,99 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: Più di 20 disponibili

      Gebunden. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Theref.

    • Lingua: Inglese

      Editore: Springer US, Springer US Aug 1998, 1998

      0306457431 / 9780306457432

      • Rilegato
      • Print on Demand

      Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 213,99

      EUR 23,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 2 disponibili

      Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This volume provides case histories illustrating the types of interdisciplinary interactions necessary to design drug candidates with optimal pharmacological, pharmaceutical, biopharmaceutical, and metabolic/pharmacokinetic properties.Key features include an incisive discussion of HIV protease inhibitors and 287 illustrations. 648 pp. Englisch.

    • Altre immagini

      Lingua: Inglese

      Editore: Springer, 1998

      0306457431 / 9780306457432

      • Rilegato
      • Print on Demand

      Da: preigu, Osnabrück, Germaniapreigu

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 186,70

      EUR 70,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 5 disponibili

      Buch. Condizione: Neu. Integration of Pharmaceutical Discovery and Development | Case Histories | Ronald T. Borchardt (u. a.) | Buch | Einband - fest (Hardcover) | Englisch | 1998 | Springer | EAN 9780306457432 | Verantwortliche Person für die EU: Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, productsafety[at]springernature[dot]com | Anbieter: preigu Print on Demand.

    • Lingua: Inglese

      Editore: Springer US, Springer Aug 1998, 1998

      0306457431 / 9780306457432

      • Rilegato
      • Print on Demand

      Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 213,99

      EUR 60,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 648 pp. Englisch.

    • Lingua: Inglese

      Editore: Humana, 1998

      0306457431 / 9780306457432

      • Rilegato
      • Print on Demand

      Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 316,62

      EUR 38,39 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This volume provides case histories illustrating the types of interdisciplinary interactions necessary to design drug candidates with optimal pharmacological, pharmaceutical, biopharmaceutical, and metabolic/pharmacokinetic properties.Key features include an incisive discussion of HIV protease inhibitors and 287 illustrations.